Techfine Biotech Secures RMB 200 Million Series A Funding to Reinforce Global Leadership in Protected Amino Acids

VCBeat recently learned that Chengdu Tachem Co., Ltd. (“Tachem”), a global leader specializing in protected amino acids and peptide drug intermediates, completed its RMB 200 million Series A financing round in August 2023.

According to reports, the funds raised in this financing round will be used to accelerate the commissioning of the company’s Phase I factory, which covers 270 mu, with a plan to add 500 metric tons of Fmoc amino acid production capacity by 2024. The funds will also support the construction of the 230-mu Phase II factory in 2024, further meeting the growing global demand for Fmoc amino acids.

Driven by favorable factors such as accelerating population aging, rising prevalence of chronic diseases, shifts in disease patterns, evolution of drug configurations, and the catalytic impact of blockbuster GLP-1 therapies, the global peptide drug market continues to thrive, leading to supply shortages of core upstream raw materials including protected amino acids, resins, and coupling agents.

However, existing manufacturers of protected amino acids are generally small, fragmented, and disorganized. They lack stable and reliable delivery systems and do not possess the strategic vision to build globally integrated industry leaders. Many companies remain in an early stage of development, characterized by low-end, undifferentiated products and inconsistent quality.

Chengdu Tachem Co., Ltd. was founded by entrepreneur Qi Wei in 2013.Upholding the philosophy of “Quality First, Technology Leadership” and practicing the values of “Integrity, Innovation, Responsibility, and Gratitude,” we are committed to continuously building a modern peptide supply chain system that is autonomous and controllable, safe and reliable, and highly competitive. Currently, the company possesses comprehensive safety, environmental protection, and compliance qualifications within the industry. It also boasts industry-leading speed in releasing new production capacity, along with a stable and professional R&D and production management team. The company’s current portfolio includes over a thousand products—such as protected amino acids, non-natural protected amino acids, peptide fragments, amino acid (linker) resins, GLP-1 side chains and their raw materials—all of which are at the industry’s leading level. This has enabled the company to rapidly secure contracts with more than 100 pharmaceutical companies and CDMO clients worldwide.

Chengdu Tachem Co., Ltd. will take the completion of this round of financing as a new starting point to further expand its leading advantage in the field of protected amino acids.Building on a foundation of efficient, stable, and high-quality large-scale production, and supported by continuously expanding R&D and sales capabilities, the company will establish a comprehensive and well-structured product portfolio. In the future, it plans to further consolidate and expand its presence in both domestic and international markets, striving to become a globally leading integrated enterprise with the largest production scale and the most complete product range.